New drug combo shows promise for hard-to-treat endometrial cancer
NCT ID NCT03008408
First seen Nov 21, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tests whether adding a third drug (ribociclib) to a two-drug combination (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. The trial involves 90 participants and aims to see if the three-drug combo can shrink tumors or stop them from growing. The approach is designed to control the disease, not cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.